Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMYNASDAQ:MODDNASDAQ:NURONASDAQ:TELA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.98-0.3%$1.01$0.69▼$1.80$25.04M-2.62262,930 shs233,810 shsMODDModular Medical$0.68+4.6%$0.89$0.63▼$2.65$36.83M0.22217,633 shs384,959 shsNURONeuroMetrix$4.55+4.4%$4.52$2.66▼$4.73$9.37M1.8216,349 shs35,522 shsTELATELA Bio$1.97+6.5%$1.38$0.86▼$5.18$77.93M0.78216,640 shs66,433 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys0.00%+15.29%+11.35%-21.60%-14.04%MODDModular Medical0.00%-10.67%-20.13%-37.72%-57.03%NURONeuroMetrix0.00%0.00%0.00%+1.22%+23.31%TELATELA Bio0.00%+19.39%+40.71%+61.48%-58.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFEMYFemasys3.6579 of 5 stars3.55.00.00.03.22.50.6MODDModular Medical1.0189 of 5 stars0.05.00.00.02.11.70.0NURONeuroMetrixN/AN/AN/AN/AN/AN/AN/AN/ATELATELA Bio3.2781 of 5 stars3.45.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 3.00Buy$8.67784.35% UpsideMODDModular Medical 0.00N/AN/AN/ANURONeuroMetrix 0.00N/AN/AN/ATELATELA Bio 2.75Moderate Buy$7.25268.02% UpsideCurrent Analyst Ratings BreakdownLatest NURO, TELA, MODD, and FEMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/13/2025FEMYFemasysJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $6.005/9/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.63M15.36N/AN/A$0.10 per share9.80MODDModular MedicalN/AN/AN/AN/A$0.42 per shareN/ANURONeuroMetrix$3.03M3.09N/AN/A$13.18 per share0.35TELATELA Bio$69.30M1.12N/AN/A$0.72 per share2.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.91N/AN/AN/A-1,242.06%-392.45%-137.15%8/14/2025 (Estimated)MODDModular Medical-$18.82M-$0.51N/A∞N/AN/A-178.13%-151.42%8/12/2025 (Estimated)NURONeuroMetrix-$6.53M-$4.59N/A∞N/A-203.71%-42.56%-39.26%8/4/2025 (Estimated)TELATELA Bio-$37.84M-$1.41N/AN/AN/A-61.00%-402.45%-62.73%8/11/2025 (Estimated)Latest NURO, TELA, MODD, and FEMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025MODDModular Medical-$0.11-$0.12-$0.01-$0.12N/AN/A5/8/2025Q1 2025FEMYFemasys-$0.17-$0.23-$0.06-$0.23$1.14 million$0.34 million5/8/2025Q1 2025TELATELA Bio-$0.21-$0.25-$0.04-$0.25$17.35 million$18.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/AMODDModular MedicalN/AN/AN/AN/AN/ANURONeuroMetrixN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.020.930.54MODDModular MedicalN/A10.6910.69NURONeuroMetrixN/A13.8812.70TELATELA Bio2.284.223.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%MODDModular Medical27.47%NURONeuroMetrix19.40%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%MODDModular Medical20.46%NURONeuroMetrix7.30%TELATELA Bio4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3025.55 million22.60 millionNot OptionableMODDModular Medical2054.25 million43.15 millionNot OptionableNURONeuroMetrix202.06 million1.90 millionNot OptionableTELATELA Bio12039.56 million37.70 millionOptionableNURO, TELA, MODD, and FEMY HeadlinesRecent News About These CompaniesWall Street Zen Downgrades TELA Bio (NASDAQ:TELA) to SellJune 14, 2025 | marketbeat.comTELA Bio Welcomes Jim Hagen with Strategic Equity GrantJune 9, 2025 | msn.comTELA Bio, Inc.: TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 7, 2025 | finanznachrichten.deTELA Bio (NASDAQ:TELA) Stock Rating Upgraded by Wall Street ZenJune 6, 2025 | marketbeat.comTELA Bio, Inc. Grants Inducement Equity Awards to New Senior Vice President Jim HagenJune 6, 2025 | quiverquant.comQTELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 4, 2025 | tmcnet.comTELA Bio, Inc. (NASDAQ:TELA) Short Interest Down 13.6% in MayJune 4, 2025 | marketbeat.comTELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia RepairJune 3, 2025 | globenewswire.comTELA Bio Names Jeffrey Blizard as President to Drive Strategic GrowthJune 3, 2025 | msn.comTELA Bio Appoints Jeffrey Blizard as President to Drive Growth and InnovationJune 2, 2025 | quiverquant.comQTELA Bio Appoints Jeffrey Blizard as PresidentJune 2, 2025 | globenewswire.comTELA Bio to Present at the 2025 Jefferies Global Healthcare ConferenceMay 25, 2025 | msn.comTELA Bio to Participate in the 2025 Jefferies Global Healthcare ConferenceMay 22, 2025 | globenewswire.comPiper Sandler Sticks to Their Hold Rating for TELA Bio (TELA)May 22, 2025 | theglobeandmail.comTELA Bio Announces Inducement Grants to New Hires with 4-Year Vesting PlanMay 12, 2025 | msn.comTELA Bio Reports Q1 2025 Growth and Product ExpansionMay 12, 2025 | msn.comTELA Bio, Inc. (TELA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comEarnings call transcript: Tela Bio Q1 2025 revenue miss, stock rises 9%May 10, 2025 | uk.investing.comTELA Bio Reports First Quarter 2025 Financial ResultsMay 10, 2025 | finance.yahoo.comTELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNURO, TELA, MODD, and FEMY Company DescriptionsFemasys NASDAQ:FEMY$0.98 0.00 (-0.33%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.03 +0.05 (+5.31%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Modular Medical NASDAQ:MODD$0.68 +0.03 (+4.61%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.67 -0.01 (-1.46%) As of 04:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.NeuroMetrix NASDAQ:NURO$4.55 +0.19 (+4.36%) Closing price 05/1/2025Extended Trading$4.55 0.00 (0.00%) As of 05/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.TELA Bio NASDAQ:TELA$1.97 +0.12 (+6.49%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$2.90 +0.93 (+47.21%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
